Skip to main content
SpringerLink
Log in

Cardiac diagnostics before oral propranolol therapy in infantile hemangioma: retrospective evaluation of 234 infants

  • Original Article
  • Published:
World Journal of Pediatrics Aims and scope Submit manuscript

Abstract

Background

The indication and extent of cardiac screening before oral propranolol therapy (OPT) in patients with infantile hemangioma (IH) has been challenged. In this study, we evaluated pre-OPT cardiac diagnostics in a pediatric IH cohort in our department.

Methods

Retrospective chart review of infants ≤ 12 months old with IH undergoing OPT. The diagnostics prior to OPT, occurrence of complications, and outcome were recorded.

Results

A total of 234 patients were evaluated. The mean age at the onset of OPT was 4.2 ± 0.3 months, the average duration of OPT was 6.1 ± 0.1 months, and the average follow-up was 12.3 ± 0.7 months. Echocardiograms and electrocardiograms were performed prior to OPT in all patients. One hundred and three (44.0%) echocardiograms revealed pathological findings, 19 (8.1%) of which were minor (including atrial septal defects, pulmonary stenosis, and patent ductus arteriosus). Pathological findings were observed in 17 (7.3%) of electrocardiograms, only one (0.4%) of which was minor (suspected cardiac arrhythmia, subsequently excluded by long-term electrocardiogram analysis). These findings did not contraindicate OPT and no severe adverse events associated with OPT occurred during the follow-up period.

Conclusions

Routine cardiac screening by electrocardiogram and echocardiogram before OPT is debatable and not routinely indicated in children with IH. Further studies are necessary to draw definite conclusions on the reasonable indication and extent of this diagnostic approach.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Hemangioma Investigator Group, Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, et al. Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr. 2007;150:291–4.

    Article  Google Scholar 

  2. Drolet BA, Esterly NB, Frieden IJ. Hemangiomas in children. N Engl J Med. 1999;341:173–81.

    Article  PubMed  CAS  Google Scholar 

  3. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358:2649–51.

    Article  PubMed  Google Scholar 

  4. Holmes WJ, Mishra A, Gorst C, Liew SH. Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas. J Plast Reconstr Aesthetic Surg. 2011;64:445–51.

    Article  CAS  Google Scholar 

  5. Fuchsmann C, Quintal MC, Giguere C, Ayari-Khalfallah S, Guibaud L, Powell J, et al. Propranolol as first-line treatment of head and neck hemangiomas. Arch Otolaryngol Head Neck Surg. 2011;137:471–8.

    Article  PubMed  Google Scholar 

  6. Schupp CJ, Kleber JB, Günther P, Holland-Cunz S. Propranolol therapy in 55 infants with infantile hemangioma: dosage, duration, adverse effects, and outcome. Pediatr Dermatol. 2011;28:640–4.

    Article  PubMed  Google Scholar 

  7. Saint-Jean M, Léauté-Labrèze C, Mazereeuw-Hautier J, Bodak N, Hamel-Teillac D, Kupfer-Bessaguet I, et al. Propranolol for treatment of ulcerated infantile hemangiomas. J Am Acad Dermatol. 2011;64:827–32.

    Article  PubMed  CAS  Google Scholar 

  8. Hogeling M, Adams S, Wargon O. A randomized controlled trial of propranolol for infantile hemangiomas. Pediatrics. 2011;128:e259–66.

    Article  PubMed  Google Scholar 

  9. Marqueling AL, Oza V, Frieden IJ, Puttgen KB. Propranolol and infantile hemangiomas four years later: a systematic review. Pediatr Dermatol. 2013;30:182–91.

    Article  PubMed  Google Scholar 

  10. Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J, Guibaud L, Baselga E, Posiunas G, et al. A randomized, controlled trial of oral propranolol in infantile hemangioma. N Engl J Med. 2015;372:735–46.

    Article  PubMed  CAS  Google Scholar 

  11. Price CJ, Lattouf C, Baum B, McLeod M, Schachner L, Duarte AM, et al. Propranolol vs corticosteroids for infantile hemangiomas: a multicenter retrospective analysis. Arch Dermatol. 2011;147:1371–6.

    Article  PubMed  CAS  Google Scholar 

  12. Kallen RJ, Mohler JH, Lin HL. Hypoglycemia: a complication of treatment of hypertension with propranolol. Clin Pediatr (Phila). 1980;19:567–8.

    Article  CAS  Google Scholar 

  13. Tomlinson B, Cronin CJ, Graham BR, Prichard BN. Haemodynamics of carvedilol in normal subjects compared with propranolol, pindolol, and labetalol. J Cardiovasc Pharmacol. 1987;10(Suppl 11):S69–75.

    Article  PubMed  CAS  Google Scholar 

  14. Lawley LP, Siegfried E, Todd JL. Propranolol treatment for hemangioma of infancy: risks and recommendations. Pediatr Dermatol. 2009;26:610–4.

    Article  PubMed  Google Scholar 

  15. Blei F, McElhinney DB, Guarini A, Presti S. Cardiac screening in infants with infantile hemangiomas before propranolol treatment. Pediatr Dermatol. 2014;31:465–70.

    Article  PubMed  Google Scholar 

  16. Raphael MF, Breugem CC, Vlasveld FA, de Graaf M, Slieker MG, Pasmans SG, et al. Is cardiovascular evaluation necessary prior to and during beta-blocker therapy for infantile hemangiomas?: A cohort study. J Am Acad Dermatol. 2015;72:465–72.

    Article  PubMed  Google Scholar 

  17. Drolet BA, Frommelt PC, Chamlin SL, Haggstrom A, Bauman NM, Chiu YE, et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131:128–40.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien–Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187–96.

    Article  PubMed  Google Scholar 

  19. Pickoff AS, Zies L, Ferrer PL, Tamer D, Wolff G, Garcia O, et al. High-dose propranolol therapy in the management of supraventricular tachycardia. J Pediatr. 1979;94:144–6.

    Article  PubMed  CAS  Google Scholar 

  20. Artman M, Grayson M, Boerth RC. Propranolol in children: safety-toxicity. Pediatrics. 1982;70:30–1.

    PubMed  CAS  Google Scholar 

  21. Baron PW, Barrow RE, Pierre EJ, Herndon DN. Prolonged use of propranolol safely decreases cardiac work in burned children. J Burn Care Rehabil. 1997;18:223–7.

    Article  PubMed  CAS  Google Scholar 

  22. Sans V, de la Roque ED, Berge J, Grenier N, Boralevi F, Mazereeuw-Hautier J, et al. Propranolol for severe infantile hemangiomas: follow-up report. Pediatrics. 2009;124:e423–31.

    Article  PubMed  Google Scholar 

  23. Buckmiller LM, Munson PD, Dyamenahalli U, Dai Z, Richter GT. Propranolol for infantile hemangiomas: early experience at a tertiary vascular anomalies center. Laryngoscope. 2010;120:676–81.

    Article  PubMed  CAS  Google Scholar 

  24. Manunza F, Syed S, Laguda B, Linward J, Kennedy H, Gholam K, et al. Propranolol for complicated infantile haemangiomas: a case series of 30 infants. Br J Dermatol. 2010;162:466–8.

    Article  PubMed  CAS  Google Scholar 

  25. Tan ST, Itinteang T, Leadbitter P. Low-dose propranolol for infantile haemangioma. J Plast Reconstr Aesthet Surg. 2011;64:292–9.

    Article  PubMed  Google Scholar 

  26. McBride JT, McBride MC, Viles PH. Hypoglycemia associated with propranolol. Pediatrics. 1973;51:1085–7.

    PubMed  CAS  Google Scholar 

  27. Horev A, Haim A, Zvulunov A. Propranolol induced hypoglycemia. Pediatr Endocrinol Rev. 2015;12:308–10.

    PubMed  Google Scholar 

  28. Dyme JL, Thampan A, Han EJ, Nyirenda TL, Kotb ME, Shin HT. Propranolol for infantile haemangiomas: initiating treatment on an outpatient basis. Cardiol Young. 2012;22:424–9.

    Article  PubMed  Google Scholar 

  29. Techasatian L, Komwilaisak P, Panombualert S, Uppala R, Jetsrisuparb C. Propranolol was effective in treating cutaneous infantile haemangiomas in Thai children. Acta Paediatr. 2016;105:e257–62.

    Article  PubMed  CAS  Google Scholar 

  30. Cushing SL, Boucek RJ, Manning SC, Sidbury R, Perkins JA. Initial experience with a multidisciplinary strategy for initiation of propranolol therapy for infantile hemangiomas. Otolaryngol Head Neck Surg. 2011;144:78–84.

    Article  PubMed  Google Scholar 

  31. McSwiney E, Murray D, Murphy M. Propranolol therapy for cutaneous infantile haemangiomas initiated safely as a day-case procedure. Eur J Pediatr. 2014;173:63–8.

    Article  PubMed  CAS  Google Scholar 

  32. Patel NJ, Bauman NM. How should propranolol be initiated for infantile hemangiomas: inpatient versus outpatient? Laryngoscope. 2014;124:1279–81.

    Article  PubMed  Google Scholar 

  33. Phillips RJ, Penington AJ, Bekhor PS, Crock CM. Use of propranolol for treatment of infantile haemangiomas in an outpatient setting. J Paediatr Child Health. 2012;48:902–6.

    Article  PubMed  Google Scholar 

  34. Solman L, Murabit A, Gnarra M, Harper JI, Syed SB, Glover M. Propranolol for infantile haemangiomas: single centre experience of 250 cases and proposed therapeutic protocol. Arch Dis Child. 2014;99:1132–6.

    Article  PubMed  Google Scholar 

  35. Botto LD, Correa A, Erickson JD. Racial and temporal variations in the prevalence of heart defects. Pediatrics. 2001;107:E32.

    Article  PubMed  CAS  Google Scholar 

  36. Shuler CO, Black GB, Jerrell JM. Population-based treated prevalence of congenital heart disease in a pediatric cohort. Pediatr Cardiol. 2013;34:606–11.

    Article  PubMed  Google Scholar 

  37. Hoffman JI. Incidence of congenital heart disease: I. Postnatal incidence. Pediatr Cardiol. 1995;16:103–13.

    Article  PubMed  CAS  Google Scholar 

  38. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002;39:1890–900.

    Article  PubMed  Google Scholar 

  39. Shaddy RE, Boucek MM, Hsu DT, Boucek RJ, Canter CE, Mahony L, et al. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA. 2007;298:1171–9.

    Article  PubMed  Google Scholar 

  40. El Ezzi O, Hohlfeld J, de Buys Roessingh A. Propranolol in infantile haemangioma: simplifying pretreatment monitoring. Swiss Med Wkly. 2014;144:w13943.

    PubMed  Google Scholar 

  41. Liu LS, Sokoloff D, Antaya RJ. Twenty-four-hour hospitalization for patients initiating systemic propranolol therapy for infantile hemangiomas—is it indicated? Pediatr Dermatol. 2013;30:554–60.

    Article  PubMed  Google Scholar 

Download references

Funding

No funding to be declared.

Author information

Authors and Affiliations

  1. Division of Pediatric Surgery, Department of General, Visceral and Transplantation Surgery, University Hospital of Heidelberg, Im Neuenheimer Feld 110, 69120, Heidelberg, Germany

    Giovanni Frongia, Ji-Oun Byeon & Patrick Günther

  2. Department of Pediatric Cardiology, Center for Pediatrics and Adolescent Medicine, University Hospital of Heidelberg, Heidelberg, Germany

    Raoul Arnold

  3. Department of General, Visceral and Transplantation Surgery, University Hospital of Heidelberg, Heidelberg, Germany

    Arianeb Mehrabi

Authors
  1. Giovanni Frongia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ji-Oun Byeon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Raoul Arnold
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Arianeb Mehrabi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Patrick Günther
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

GF contributed to study design, data collection, data analysis and interpretation, and manuscript drafting. JB contributed to data collection, data analysis and interpretation, and manuscript drafting. RA contributed to critical revision of the manuscript. AM contributed to critical revision of the manuscript. PG contributed to study design, and critical revision of the manuscript. All authors approved the final version of the manuscript.

Corresponding author

Correspondence to Giovanni Frongia.

Ethics declarations

Ethical approval

This study was approved by the Ethical Committee of the University of Heidelberg, Germany.

Conflict of interest

The authors report no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Frongia, G., Byeon, JO., Arnold, R. et al. Cardiac diagnostics before oral propranolol therapy in infantile hemangioma: retrospective evaluation of 234 infants. World J Pediatr 14, 254–258 (2018). https://doi.org/10.1007/s12519-018-0137-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12519-018-0137-7

Keywords

Search

Navigation